الصفحة الرئيسية>>Signaling Pathways>> GPCR/G protein>> Prostaglandin Receptor>>CAY10471 Racemate

CAY10471 Racemate

رقم الكتالوجGC35620

CAY10471 Racemate (TM30089 Racemate) هو مضاد CRTH2 لمستقبل البروستاغلاندين D2 قوي وانتقائي للغاية ، مع Ki 0.6 نانومتر لـ hCRTH2 ، انتقائي على مستقبل الثرموبوكسان البشري A2 TP (Ki ،> 10000 نانومتر) أو مستقبل PGD2 DP (Ki ، 1200 نانومتر) )

Products are for research use only. Not for human use. We do not sell to patients.

CAY10471 Racemate التركيب الكيميائي

Cas No.: 844639-57-2

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
112٫00
متوفر
5mg
102٫00
متوفر
10mg
167٫00
متوفر
25mg
362٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CAY10471 Racemate (TM30089 Racemate) is a potent and highly selective prostaglandin D2 receptor CRTH2 antagonist, with a Ki of 0.6 nM for hCRTH2, selective over human thromboxane A2 receptor TP (Ki, >10000 nM) or PGD2 receptor DP (Ki, 1200 nM). CAY10471 Racemate also has effect on mouse and rat orthologs of CRTH2[1]. Ki: 0.6 nM (CRTH2), 1200 nM (DP)[1]

CAY10471 Racemate (Compound 13) inhibits PGD2-induced inositol phosphate or cAMP formation, suppresses β-arrestin translocation with IC50s of 12 and 3 nM, respectively[1].

[1]. Ulven T, et al. Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist. J Med Chem. 2005 Feb 24;48(4):897-900.

مراجعات

Review for CAY10471 Racemate

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CAY10471 Racemate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.